Peter H. Seeberger
Fondateur chez TACALYX GmbH
Profil
Peter H.
Seeberger is the founder of i2chem, Inc. (2005) and Synglyco, Inc. (2001).
He was also the founder of TACALYX GmbH.
Currently, he held the position of Director at Tesfa-ilg Stiftung, and was a Professor at Freie Universität Berlin and Max Planck Institute of Colloids & Interfaces.
Previously, he was a Professor at Massachusetts Institute of Technology (2002-2010), Swiss Federal Institute of Technology, and Affiliate Professor at Sanford Burnham Prebys Medical Discovery Institute.
He received his doctorate degree from The University of Colorado in 1995.
Postes actifs de Peter H. Seeberger
| Sociétés | Poste | Début |
|---|---|---|
| Tesfa-ilg Stiftung | Directeur/Membre du Conseil | - |
| Freie Universität Berlin | Corporate Officer/Principal | - |
| Max Planck Institute of Colloids & Interfaces | Corporate Officer/Principal | - |
TACALYX GmbH
 TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Fondateur | - |
Anciens postes connus de Peter H. Seeberger
| Sociétés | Poste | Fin |
|---|---|---|
i2chem, Inc.
 i2chem, Inc. SemiconductorsElectronic Technology i2chem, Inc. develops integrated microchemical systems based on silicon micro reactors. The firm is a startup company commercializing micro reactors for chemical applications. The company was founded by Klavs Jensen & Peter H. Seeberger in 2005 and is headquartered in Sunnyvale, CA. | Fondateur | - |
Sanford Burnham Prebys Medical Discovery Institute
 Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | - |
| Swiss Federal Institute of Technology | Corporate Officer/Principal | - |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Synglyco, Inc.
 Synglyco, Inc. Pharmaceuticals: MajorHealth Technology Synglyco, Inc. develops novel vaccines using synthetic carbohydrates. The firm's cutting edge technology enables the rapid, milligram to kilogram production of synthetic carbohydrates for use in drug discovery and industrial applications. Its proprietary platform generates significant quantities of chemically pure, complex carbohydrates through automated and manual chemical synthesis. The company was founded by Peter H. Seeberger, Carmichael S. Roberts Jr. Obadiah J. Plante and Louis Schofield on June 18, 2001 and is headquartered in New York, NY. | Fondateur | - |
Formation de Peter H. Seeberger
| The University of Colorado | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Synglyco, Inc.
Synglyco, Inc. Pharmaceuticals: MajorHealth Technology Synglyco, Inc. develops novel vaccines using synthetic carbohydrates. The firm's cutting edge technology enables the rapid, milligram to kilogram production of synthetic carbohydrates for use in drug discovery and industrial applications. Its proprietary platform generates significant quantities of chemically pure, complex carbohydrates through automated and manual chemical synthesis. The company was founded by Peter H. Seeberger, Carmichael S. Roberts Jr. Obadiah J. Plante and Louis Schofield on June 18, 2001 and is headquartered in New York, NY. | Health Technology |
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Health Services |
i2chem, Inc.
i2chem, Inc. SemiconductorsElectronic Technology i2chem, Inc. develops integrated microchemical systems based on silicon micro reactors. The firm is a startup company commercializing micro reactors for chemical applications. The company was founded by Klavs Jensen & Peter H. Seeberger in 2005 and is headquartered in Sunnyvale, CA. | Electronic Technology |
| Tesfa-ilg Stiftung | |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Commercial Services |